Trial Profile
A study to compare the efficacy of concurrent TACE+sorafenib versus TACE alone in patients with unresectable hepatocellular carcinoma (uHCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Feb 2017 New trial record